Along with a recent report of detectable nasopharyngeal IgA responses in a minority of recipients of an influenza-vectored SARS-CoV-2 vaccine,2 this is one of the first demonstrations of such immunogenicity by a mucosal SARS-CoV-2 vaccine. Here, CD79A is linked to influenza.